DAS28, 28 joint disease activity score

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register
K Hyrich, D Symmons, K Watson, A Silman, BSRBR Control Centre Consortium

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 895-898; DOI: 10.1136/ard.2005.043158
Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
A A den Broeder, E de Jong, M J A M Franssen, M E C Jeurissen, M Flendrie, F H J van den Hoogen

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 760-762; DOI: 10.1136/ard.2004.033662
Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab
A Kuuliala, R Nissinen, H Kautiainen, H Repo, M Leirisalo-Repo

Annals of the Rheumatic Diseases Jan 2006, 65 (1) 26-29; DOI: 10.1136/ard.2004.034728
Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis
A Häkkinen, H Kautiainen, P Hannonen, J Ylinen, H Mäkinen, T Sokka

Annals of the Rheumatic Diseases Jan 2006, 65 (1) 30-34; DOI: 10.1136/ard.2004.034769
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
H A Chen, K C Lin, C H Chen, H T Liao, H P Wang, H N Chang, C Y Tsai, C T Chou

Annals of the Rheumatic Diseases Jan 2006, 65 (1) 35-39; DOI: 10.1136/ard.2005.038851
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis
M M J Nielen, A R van der Horst, D van Schaardenburg, I E van der Horst-Bruinsma, R J van de Stadt, L Aarden, B A C Dijkmans, D Hamann

Annals of the Rheumatic Diseases Aug 2005, 64 (8) 1199-1204; DOI: 10.1136/ard.2004.029389
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12
M van Oosterhout, E W N Levarht, J K Sont, T W J Huizinga, R E M Toes, J M van Laar

Annals of the Rheumatic Diseases Apr 2005, 64 (4) 537-543; DOI: 10.1136/ard.2004.024927
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, J S Smolen

Annals of the Rheumatic Diseases Apr 2005, 64 (4) 564-568; DOI: 10.1136/ard.2003.014985
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
E N van Roon, T L T A Jansen, M A F J van de Laar, M Janssen, J P Yska, R Keuper, P M Houtman, J R B J Brouwers

Annals of the Rheumatic Diseases Apr 2005, 64 (4) 569-574; DOI: 10.1136/ard.2004.025205
Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists
J Sany, P Bourgeois, A Saraux, S Durieux, A Lafuma, J P Daurès, F Guillemin, J Sibilia

Annals of the Rheumatic Diseases Oct 2004, 63 (10) 1235-1240; DOI: 10.1136/ard.2003.013110

Main menu

DAS28, 28 joint disease activity score

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

DAS28, 28 joint disease activity score

Pages